We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BRAND FIRMS MAY SEEK TO DELAY GENERIC COMPETITION THROUGH NONLISTED PATENTS
BRAND FIRMS MAY SEEK TO DELAY GENERIC COMPETITION THROUGH NONLISTED PATENTS
January 27, 2004
While reforms to the Hatch-Waxman Act aim to cut down on abuses of the drug patent system, a provision in the law may still let brand firms delay generic competition by simply not listing all of their patents in the FDA’s Orange Book.